In the phase 3 EBBINGHAUS trial, researchers examined the cognitive effects of evolocumab (Repatha/Amgen). Lead author, Robert Giugliano, MD, cardiologist at Brigham and Women’s Hospital and associate professor at Harvard Medical School, sat down with MD Magazine to go over the trial at the 66th Scientific Session of the American College of Cardiology (ACC 2017) in Washington, District of Columbia.
